REG - Malin Corp PLC - Kymab wins UK Supreme Court case

MalinAnnouncement

24/06/2020 15:05

RNS Number : 9699Q
  
Malin Corporation PLC
  
24 June 2020
  
 

Malin Corporation plc
 
Kymab wins UK Supreme Court case against Regeneron 
 
Dublin-Ireland, 24 June 2020: Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies, today is pleased to note that Kymab Limited (Kymab), a clinical-stage biopharmaceutical company and one of Malin's Priority Assets, has won its UK Supreme Court case against Regeneron Pharmaceuticals, Inc (Regeneron). The Supreme Court held that all of the claims of two patents (European Patents EP(UK) 1 360 287 and EP(UK) 2 264 163, the 'Murphy patents') owned by Regeneron that were asserted against Kymab are invalid. Regeneron initiated these patent infringement proceedings against Kymab in 2013. The Supreme Court's decision upholds the February 2016 UK High Court decision to revoke the claims and reverses the UK Appeal Court's determination that they were valid. 
 
This ruling in the UK follows Regeneron's unsuccessful attempt to invalidate five Kymab patents in the US covering genetically modified mice and the human antibody therapeutics produced from these mice earlier this year. Regeneron was also recently unsuccessful with challenges to Kymab patents in Japan and Australia.
 
"We congratulate the Kymab management team and board for their resilience in defending this case in the UK since 2013 and are delighted with the UK Supreme Court's ruling invalidating Regeneron's patent claims," said Darragh Lyons, Malin Chief Executive Officer. "We look forward to further progress from this Priority Asset, namely the important clinical data from Kymab's pipeline over the coming months, particularly the Phase 2a clinical data for the anti-OX40 ligand-targeting antibody in atopic dermatitis."
 
A copy of Kyamb's press release is available to view here: https://www.kymab.com/news-and-events/news/2020/jun/24/kymab-wins-supreme-court-case-against-regeneron/
 
Kymab is a clinical-stage biopharmaceutical company based in Cambridge, UK, developing a deep pipeline of novel antibody-based therapies in a broad range of indications. The Company generates its product candidates using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab's platforms have been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies allows for the identification of antibodies with optimal drug-like properties.
 
ENDS
 
About Malin Corporation plc
Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com  

For further information please contact:
 
Malin 
Jessica Bergin, Investor Relations & External Reporting
Tel: +353 (0)1 901 5700
investorrelations@malinplc.com
 
Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)
Brian Garrahy / Daragh O'Reilly
Tel: +353 1 679 6363
 
Liberum (Joint Broker)
Bidhi Bhoma / Euan Brown
Tel: +44 (0) 20 3100 2000
 
Consilium Strategic Communications 
Mary-Jane Elliott / Chris Welsh
Tel: +44 (0)20 3709 5700
malin@consilium-comms.com 
 
Powerscourt (Irish Media enquiries)          
Eavan Gannon
Tel: +353 87 236 5973                            
malin@powerscourt-group.com  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCBDGDLIUDDGGS